Mechanism of Action/Pathway Profiles

Mechanism of Action Magnifier – 2016 Desk Reference

Welcome to the inaugural edition of our annual Mechanism of Action Magnifier™! The Magnifier series is an exclusive supplement brought to you by the publishers of Personalized Medicine in Oncology (PMO) to delve into the biochemical interaction through which an oncology drug produces its pharmacological effect.

View Supplement

Mechanism of Pathway: Phosphatidylserine, an Immune-Modulating Checkpoint, Ushers in the Next Wave of Immuno-Oncology Targets
  • Phosphatidylserine (PS) is an immune checkpoint distinct from PD-1/PD-L1, CTLA-4, and other antagonists or agonists of T-cell activation
  • Tumors compromise the body’s normal immunosuppressive process of clearance/disposal of dying cells through PS-signaling mechanisms to evade immune detection
  • PS exposure in the tumor microenvironment is immunosuppressive and increases in response to chemotherapy and radiation therapy
  • Bavituximab is an investigational monoclonal antibody that targets PS and is believed to override PS-mediated immunosuppressive signaling in tumors prevalent in the tumor microenvironment, as well as to provide an immune-activating signal through Fc-γ receptor signaling

View Supplement

Mechanism of Action: Key Advances in Hematology Oncology
As evidenced by the 2013 annual meetings of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the European Hematology Association (EHA), the pace at which scientific knowledge is influencing cancer drug development is astounding. Breakthroughs in our collective understanding of the underlying biology of solid and liquid tumors have revolutionized cancer treatment compared with as few as 5 years ago.

View Supplement